Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2016, Article ID 8734827, 7 pages
http://dx.doi.org/10.1155/2016/8734827
Research Article

In Patients with Coronary Artery Disease and Type 2 Diabetes, SIRT1 Expression in Circulating Mononuclear Cells Is Associated with Levels of Inflammatory Cytokines but Not with Coronary Lesions

1Department of Cardiovascular Surgery, Shanghai Tenth People’s Hospital, Tongji University School of Medicine, Shanghai 200072, China
2Department of Cardiology, Shanghai Tenth People’s Hospital, Tongji University School of Medicine, Shanghai 200072, China

Received 6 December 2015; Revised 29 February 2016; Accepted 13 March 2016

Academic Editor: Ramazan Akdemir

Copyright © 2016 Yuanmin Li et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. S. H. Ley, O. Hamdy, V. Mohan, and F. B. Hu, “Prevention and management of type 2 diabetes: dietary components and nutritional strategies,” The Lancet, vol. 383, no. 9933, pp. 1999–2007, 2014. View at Publisher · View at Google Scholar · View at Scopus
  2. P. S. Baweja, P. B. Sandesara, and M. J. Ashraf, “Asymptomatic coronary artery disease in type II diabetes,” Missouri Medicine, vol. 111, no. 1, pp. 73–79, 2014. View at Google Scholar · View at Scopus
  3. M. G. Zeadin, C. I. Petlura, and G. H. Werstuck, “Molecular mechanisms linking diabetes to the accelerated development of atherosclerosis,” Canadian Journal of Diabetes, vol. 37, no. 5, pp. 345–350, 2013. View at Publisher · View at Google Scholar · View at Scopus
  4. L. H. Young, F. J. T. Wackers, D. A. Chyun et al., “Cardiac outcomes after screening for asymptomatic coronary artery disease in patients with type 2 diabetes the DIAD study: a randomized controlled trial,” The Journal of the American Medical Association, vol. 301, no. 15, pp. 1547–1555, 2009. View at Publisher · View at Google Scholar · View at Scopus
  5. E. J. Armstrong, J. Waltenberger, and J. H. Rogers, “Percutaneous coronary intervention in patients with diabetes: current concepts and future directions,” Journal of Diabetes Science and Technology, vol. 8, no. 3, pp. 581–589, 2014. View at Publisher · View at Google Scholar · View at Scopus
  6. G. R. Myers and W. S. Weintraub, “Coronary artery disease: revascularization strategies for patients with CAD and diabetes,” Nature Reviews Cardiology, vol. 7, no. 7, pp. 364–366, 2010. View at Publisher · View at Google Scholar · View at Scopus
  7. M. J. Zellweger, M. Maraun, H. H. Osterhues et al., “Progression to overt or silent cad in asymptomatic patients with diabetes mellitus at high coronary risk: main findings of the prospective multicenter BARDOT trial with a pilot randomized treatment substudy,” JACC: Cardiovascular Imaging, vol. 7, no. 10, pp. 1001–1010, 2014. View at Publisher · View at Google Scholar · View at Scopus
  8. K. M. Hirahatake, J. L. Slavin, K. C. Maki, and S. H. Adams, “Associations between dairy foods, diabetes, and metabolic health: potential mechanisms and future directions,” Metabolism: Clinical and Experimental, vol. 63, no. 5, pp. 618–627, 2014. View at Publisher · View at Google Scholar · View at Scopus
  9. M. Quiñones, O. Al-Massadi, J. Fernø, and R. Nogueiras, “Cross-talk between SIRT1 and endocrine factors: effects on energy homeostasis,” Molecular and Cellular Endocrinology, vol. 397, no. 1-2, pp. 42–50, 2014. View at Publisher · View at Google Scholar · View at Scopus
  10. X. Hou, S. Xu, K. A. Maitland-Toolan et al., “SIRT1 regulates hepatocyte lipid metabolism through activating AMP-activated protein kinase,” Journal of Biological Chemistry, vol. 283, no. 29, pp. 20015–20026, 2008. View at Publisher · View at Google Scholar · View at Scopus
  11. M. Kitada and D. Koya, “SIRT1 in type 2 diabetes: mechanisms and therapeutic potential,” Diabetes and Metabolism Journal, vol. 37, no. 5, pp. 315–325, 2013. View at Publisher · View at Google Scholar · View at Scopus
  12. S. Stein, C. Lohmann, N. Schäfer et al., “SIRT1 decreases Lox-1-mediated foam cell formation in atherogenesis,” European Heart Journal, vol. 31, no. 18, pp. 2301–2309, 2010. View at Publisher · View at Google Scholar · View at Scopus
  13. Y. Hu, L. Wang, S. Chen et al., “Association between the SIRT1 mRNA expression and acute coronary syndrome,” Journal of Atherosclerosis and Thrombosis, vol. 22, no. 2, pp. 165–182, 2015. View at Publisher · View at Google Scholar · View at Scopus
  14. A. Breitenstein, C. A. Wyss, R. D. Spescha et al., “Peripheral blood monocyte sirt1 expression is reduced in patients with coronary artery disease,” PLoS ONE, vol. 8, no. 1, Article ID e53106, 2013. View at Publisher · View at Google Scholar · View at Scopus
  15. R. Guo, Y. Su, B. Liu, S. Li, S. Zhou, and Y. Xu, “Resveratrol suppresses oxidised low-density lipoprotein-induced macrophage apoptosis through inhibition of intracellular reactive oxygen species generation, LOX-1, and the p38 MAPK pathway,” Cellular Physiology and Biochemistry, vol. 34, no. 2, pp. 603–616, 2014. View at Publisher · View at Google Scholar · View at Scopus
  16. S. Stein, N. Schäfer, A. Breitenstein et al., “SIRT1 reduces endothelial activation without affecting vascular function in ApoE-/- mice,” Aging, vol. 2, no. 6, pp. 353–360, 2010. View at Publisher · View at Google Scholar · View at Scopus
  17. S. Carter, S. Miard, C. Roy-Bellavance et al., “Sirt1 inhibits resistin expression in aortic stenosis,” PLoS ONE, vol. 7, no. 4, Article ID e35110, 2012. View at Publisher · View at Google Scholar · View at Scopus
  18. H.-T. Zeng, Y.-C. Fu, W. Yu et al., “SIRT1 prevents atherosclerosis via liver-X-receptor and NF-κB signaling in a U937 cell model,” Molecular Medicine Reports, vol. 8, no. 1, pp. 23–28, 2013. View at Publisher · View at Google Scholar · View at Scopus
  19. American Diabetes Association, “Classification and diagnosis of diabetes,” Diabetes Care, vol. 38, supplement, pp. S8–S16, 2015. View at Google Scholar
  20. SYNTAX Score, http://www.syntaxscore.com.
  21. G. Sianos, M. A. Morel, A. P. Kappetein et al., “The SYNTAX Score: an angiographic tool grading the complexity of coronary artery disease,” EuroIntervention, vol. 1, no. 2, pp. 219–227, 2005. View at Google Scholar
  22. L. R. Staimez, M. B. E. Weber, and E. W. Gregg, “The role of lifestyle change for prevention of cardiovascular disease in diabetes,” Current atherosclerosis reports, vol. 16, no. 12, article 460, 2014. View at Publisher · View at Google Scholar · View at Scopus
  23. R. Guo, B. Liu, K. Wang, S. Zhou, W. Li, and Y. Xu, “Resveratrol ameliorates diabetic vascular inflammation and macrophage infiltration in db/db mice by inhibiting the NF-κB pathway,” Diabetes and Vascular Disease Research, vol. 11, no. 2, pp. 92–102, 2014. View at Publisher · View at Google Scholar · View at Scopus
  24. R. Guo, W. Liu, B. Liu, B. Zhang, W. Li, and Y. Xu, “SIRT1 suppresses cardiomyocyte apoptosis in diabetic cardiomyopathy: an insight into endoplasmic reticulum stress response mechanism,” International Journal of Cardiology, vol. 191, pp. 36–45, 2015. View at Publisher · View at Google Scholar
  25. M. Kitada, S. Kume, K. Kanasaki, A. Takeda-Watanabe, and D. Koya, “Sirtuins as possible drug targets in type 2 diabetes,” Current Drug Targets, vol. 14, no. 6, pp. 622–636, 2013. View at Publisher · View at Google Scholar · View at Scopus
  26. A. B. Crujeiras, D. Parra, E. Goyenechea, and J. A. Martínez, “Sirtuin gene expression in human mononuclear cells is modulated by caloric restriction,” European Journal of Clinical Investigation, vol. 38, no. 9, pp. 672–678, 2008. View at Publisher · View at Google Scholar · View at Scopus
  27. S. V. de Kreutzenberg, G. Ceolotto, I. Papparella et al., “Downregulation of the longevity-associated protein sirtuin 1 in insulin resistance and metabolic syndrome: potential biochemical mechanisms,” Diabetes, vol. 59, no. 4, pp. 1006–1015, 2010. View at Publisher · View at Google Scholar · View at Scopus
  28. R. Song, W. Xu, Y. Chen, Z. Li, Y. Zeng, and Y. Fu, “The expression of sirtuins 1 and 4 in peripheral blood leukocytes from patients with type 2 diabetes,” European Journal of Histochemistry, vol. 55, no. 1, article e10, 2011. View at Publisher · View at Google Scholar · View at Scopus
  29. R. Caruso, I. Marafini, E. Franzè et al., “Defective expression of SIRT1 contributes to sustain inflammatory pathways in the gut,” Mucosal Immunology, vol. 7, no. 6, pp. 1467–1479, 2014. View at Publisher · View at Google Scholar · View at Scopus
  30. G. Ceolotto, S. V. De Kreutzenberg, A. Cattelan et al., “Sirtuin 1 stabilization by HuR represses TNF-α-and glucose-induced E-selectin release and endothelial cell adhesiveness in vitro: relevance to human metabolic syndrome,” Clinical Science, vol. 127, no. 7, pp. 449–461, 2014. View at Publisher · View at Google Scholar · View at Scopus
  31. A. Storka, G. Führlinger, M. Seper et al., “E. coli endotoxin modulates the expression of sirtuin proteins in PBMC in humans,” Mediators of Inflammation, vol. 2013, Article ID 876943, 6 pages, 2013. View at Publisher · View at Google Scholar · View at Scopus
  32. S. Matsushima and J. Sadoshima, “The role of sirtuins in cardiac disease,” American Journal of Physiology—Heart and Circulatory Physiology, vol. 309, no. 9, pp. H1375–H1389, 2015. View at Publisher · View at Google Scholar · View at Scopus
  33. I. Gorenne, S. Kumar, K. Gray et al., “Vascular smooth muscle cell sirtuin 1 protects against dna damage and inhibits atherosclerosis,” Circulation, vol. 127, no. 3, pp. 386–396, 2013. View at Publisher · View at Google Scholar · View at Scopus
  34. N. D'Onofrio, M. Vitiello, R. Casale, L. Servillo, A. Giovane, and M. L. Balestrieri, “Sirtuins in vascular diseases: emerging roles and therapeutic potential,” Biochimica et Biophysica Acta—Molecular Basis of Disease, vol. 1852, no. 7, pp. 1311–1322, 2015. View at Publisher · View at Google Scholar · View at Scopus
  35. S. Kume, T. Uzu, A. Kashiwagi, and D. Koya, “SIRT1, a calorie restriction mimetic, in a new therapeutic approach for type 2 diabetes mellitus and diabetic vascular complications,” Endocrine, Metabolic and Immune Disorders—Drug Targets, vol. 10, no. 1, pp. 16–24, 2010. View at Publisher · View at Google Scholar · View at Scopus
  36. H.-C. Su, L.-M. Hung, and J.-K. Chen, “Resveratrol, a red wine antioxidant, possesses an insulin-like effect in streptozotocin-induced diabetic rats,” American Journal of Physiology—Endocrinology and Metabolism, vol. 290, no. 6, pp. E1339–E1346, 2006. View at Publisher · View at Google Scholar · View at Scopus
  37. M. Lagouge, C. Argmann, Z. Gerhart-Hines et al., “Resveratrol improves mitochondrial function and protects against metabolic disease by activating SIRT1 and PGC-1α,” Cell, vol. 127, no. 6, pp. 1109–1122, 2006. View at Publisher · View at Google Scholar · View at Scopus
  38. J. P. Crandall, V. Oram, G. Trandafirescu et al., “Pilot study of resveratrol in older adults with impaired glucose tolerance,” Journals of Gerontology A: Biological Sciences and Medical Sciences, vol. 67, no. 12, pp. 1307–1312, 2012. View at Publisher · View at Google Scholar · View at Scopus
  39. K. Magyar, R. Halmosi, A. Palfi et al., “Cardioprotection by resveratrol: a human clinical trial in patients with stable coronary artery disease,” Clinical Hemorheology and Microcirculation, vol. 50, no. 3, pp. 179–187, 2012. View at Publisher · View at Google Scholar · View at Scopus
  40. J. C. Milne, P. D. Lambert, S. Schenk et al., “Small molecule activators of SIRT1 as therapeutics for the treatment of type 2 diabetes,” Nature, vol. 450, no. 7170, pp. 712–716, 2007. View at Publisher · View at Google Scholar · View at Scopus
  41. V. Libri, A. P. Brown, G. Gambarota et al., “A pilot randomized, placebo controlled, double blind phase I trial of the novel SIRT1 activator SRT2104 in elderly volunteers,” PLoS ONE, vol. 7, no. 12, Article ID e51395, 2012. View at Publisher · View at Google Scholar · View at Scopus
  42. M. M. Poulsen, P. F. Vestergaard, B. F. Clasen et al., “High-dose resveratrol supplementation in obese men: an investigator-initiated, randomized, placebo-controlled clinical trial of substrate metabolism, insulin sensitivity, and body composition,” Diabetes, vol. 62, no. 4, pp. 1186–1195, 2013. View at Publisher · View at Google Scholar · View at Scopus
  43. R. D. Semba, L. Ferrucci, B. Bartali et al., “Resveratrol levels and all-cause mortality in older community-dwelling adults,” JAMA Internal Medicine, vol. 174, no. 7, pp. 1077–1084, 2014. View at Publisher · View at Google Scholar · View at Scopus